Champions Oncology Stock Buy Hold or Sell Recommendation
| CSBR Stock | USD 9.23 0.34 3.82% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Champions Oncology is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Champions Oncology within the specified time frame.
Check out Champions Oncology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide. Note, we conduct extensive research on individual companies such as Champions and provide practical buy, sell, or hold advice based on investors' constraints. Champions Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Champions |
Execute Champions Oncology Buy or Sell Advice
The Champions recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Champions Oncology. Macroaxis does not own or have any residual interests in Champions Oncology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Champions Oncology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Good | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Champions Oncology Trading Alerts and Improvement Suggestions
| Champions Oncology is way too risky over 90 days horizon | |
| Champions Oncology appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 50.16 M. Net Loss for the year was (7.28 M) with profit before overhead, payroll, taxes, and interest of 23.97 M. | |
| Champions Oncology currently holds about 8.06 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: Champions Oncology Third Quarter 2025 Earnings EPS US0.33 |
Champions Oncology Returns Distribution Density
The distribution of Champions Oncology's historical returns is an attempt to chart the uncertainty of Champions Oncology's future price movements. The chart of the probability distribution of Champions Oncology daily returns describes the distribution of returns around its average expected value. We use Champions Oncology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Champions Oncology returns is essential to provide solid investment advice for Champions Oncology.
| Mean Return | 1.25 | Value At Risk | -8.29 | Potential Upside | 10.88 | Standard Deviation | 6.31 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Champions Oncology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Champions Stock Institutional Investors
The Champions Oncology's institutional investors refer to entities that pool money to purchase Champions Oncology's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | State Street Corp | 2024-12-31 | 26.6 K | Bank Of America Corp | 2024-12-31 | 25.3 K | Cambridge Invest Research Advisors, Inc. | 2024-12-31 | 12.3 K | Mesirow Fin Investmt Mgmt Intl Equity | 2024-12-31 | 12 K | Susquehanna International Group, Llp | 2024-12-31 | 11.5 K | Virtu Financial Llc | 2024-12-31 | 11.1 K | Millennium Management Llc | 2024-12-31 | 10.9 K | Citadel Advisors Llc | 2024-12-31 | 10.9 K | Tower Research Capital Llc | 2024-12-31 | 1.6 K | Battery Management Corp | 2024-12-31 | 2.4 M | Nea Management Company, Llc | 2024-12-31 | 1.7 M |
Champions Oncology Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (3.7M) | 4.3M | 1.1M | (7.5M) | (6.8M) | (6.4M) | |
| Free Cash Flow | (5.0M) | 4.1M | 1.1M | (7.0M) | (6.3M) | (6.0M) | |
| Depreciation | 1.2M | 1.6M | 2.2M | 1.9M | 2.1M | 2.3M | |
| Other Non Cash Items | 323K | 1.1M | 952K | 2.0M | 2.3M | 2.4M | |
| Capital Expenditures | 3.3M | 2.4M | 2.9M | 836K | 961.4K | 610.0K | |
| Net Income | 334K | 548K | (5.3M) | (7.3M) | (6.5M) | (6.2M) | |
| End Period Cash Flow | 4.7M | 9.0M | 10.1M | 2.6M | 3.0M | 3.7M | |
| Change Receivables | (670K) | (2.3M) | (2.8M) | 1.3M | 1.2M | 1.2M | |
| Change To Netincome | 1.2M | 970K | 1.2M | 1.9M | 1.7M | 1.6M | |
| Investments | (3.2M) | (2.4M) | (2.9M) | (836K) | (752.4K) | (790.0K) |
Champions Oncology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Champions Oncology or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Champions Oncology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Champions stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 1.36 | |
β | Beta against Dow Jones | 1.09 | |
σ | Overall volatility | 5.44 | |
Ir | Information ratio | 0.21 |
Champions Oncology Volatility Alert
Champions Oncology is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Champions Oncology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Champions Oncology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Champions Oncology Fundamentals Vs Peers
Comparing Champions Oncology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Champions Oncology's direct or indirect competition across all of the common fundamentals between Champions Oncology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Champions Oncology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Champions Oncology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Champions Oncology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Champions Oncology to competition |
| Fundamentals | Champions Oncology | Peer Average |
| Return On Equity | -1.55 | -0.31 |
| Return On Asset | -0.0082 | -0.14 |
| Profit Margin | (0.01) % | (1.27) % |
| Operating Margin | 0.05 % | (5.51) % |
| Current Valuation | 125.02 M | 16.62 B |
| Shares Outstanding | 13.7 M | 571.82 M |
| Shares Owned By Insiders | 25.89 % | 10.09 % |
| Shares Owned By Institutions | 47.81 % | 39.21 % |
| Number Of Shares Shorted | 98.84 K | 4.71 M |
| Price To Earning | 220.00 X | 28.72 X |
| Price To Book | 22.27 X | 9.51 X |
| Price To Sales | 2.36 X | 11.42 X |
| Revenue | 50.16 M | 9.43 B |
| Gross Profit | 23.97 M | 27.38 B |
| EBITDA | (5.05 M) | 3.9 B |
| Net Income | (7.28 M) | 570.98 M |
| Cash And Equivalents | 8.06 M | 2.7 B |
| Cash Per Share | 0.60 X | 5.01 X |
| Total Debt | 7.43 M | 5.32 B |
| Debt To Equity | 1.03 % | 48.70 % |
| Current Ratio | 1.11 X | 2.16 X |
| Book Value Per Share | (0.14) X | 1.93 K |
| Cash Flow From Operations | (6.14 M) | 971.22 M |
| Short Ratio | 2.69 X | 4.00 X |
| Earnings Per Share | 0.45 X | 3.12 X |
| Target Price | 12.0 | |
| Number Of Employees | 210 | 18.84 K |
| Beta | 0.2 | -0.15 |
| Market Capitalization | 126.44 M | 19.03 B |
| Total Asset | 26.13 M | 29.47 B |
| Retained Earnings | (84.59 M) | 9.33 B |
| Working Capital | (7.9 M) | 1.48 B |
| Current Asset | 4.34 M | 9.34 B |
Note: Acquisition by Sidransky David of 8045 shares of Champions Oncology at 10.1 subject to Rule 16b-3 [view details]
Champions Oncology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Champions . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Champions Oncology Buy or Sell Advice
When is the right time to buy or sell Champions Oncology? Buying financial instruments such as Champions Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Champions Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.